Gene expression test distinguishes between breast cancer patients at high or low risk of late recurrence
Gene expression test distinguishes between breast cancer patients at high or low risk of late recurrence
Long-term effectiveness of SERMs for preventing breast cancer
Closing the cancer divide: Implementing the diagonal approach
Pelvic radiotherapy and androgen blockade for high risk prostate cancer
Results of a randomised phase 2 study of PD 0332991
The AZURE translational study
Prognostic signatures in colon cancer
HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment
Gestational trophoblastic disease tumours in high risk patients
State of PARP inhibitors and anti-angiogenics
Defining and advancing individualised medicine
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)